216 related articles for article (PubMed ID: 10613317)
1. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Renshaw AA; Tomaszewski JE; Richie JP; Wein A
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1227-33. PubMed ID: 10613317
[TBL] [Abstract][Full Text] [Related]
2. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Tomaszewski JE; Wein A
Cancer; 2000 May; 88(9):2110-5. PubMed ID: 10813723
[TBL] [Abstract][Full Text] [Related]
4. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
5. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
6. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA Cheng GC; Chen MH; Whittington R; Malkowicz SB; Schnall MD; Tomaszewski JE; D'Amico AV
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):64-70. PubMed ID: 12504037
[TBL] [Abstract][Full Text] [Related]
8. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
9. Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV.
D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Tomaszewski JE; Wein A; Coleman CN
Int J Radiat Oncol Biol Phys; 1997 Sep; 39(2):335-40. PubMed ID: 9308936
[TBL] [Abstract][Full Text] [Related]
10. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
11. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.
Fukunaga-Johnson N; Sandler HM; McLaughlin PW; Strawderman MS; Grijalva KH; Kish KE; Lichter AS
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):311-7. PubMed ID: 9226317
[TBL] [Abstract][Full Text] [Related]
12. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
[TBL] [Abstract][Full Text] [Related]
13. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
[TBL] [Abstract][Full Text] [Related]
14. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Wein A; Tomaszewski JE; Coleman CN
Cancer; 1998 Jan; 82(2):334-41. PubMed ID: 9445191
[TBL] [Abstract][Full Text] [Related]
15. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer.
Valicenti RK; Chervoneva I; Gomella LG
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1093-7. PubMed ID: 15001249
[TBL] [Abstract][Full Text] [Related]
16. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
17. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy.
D'Amico AV; Renshaw AA; Arsenault L; Schultz D; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):841-6. PubMed ID: 10571187
[TBL] [Abstract][Full Text] [Related]
19. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Fondurulia J; Chen MH; Kaplan I; Beard CJ; Tomaszewski JE; Renshaw AA; Wein A; Coleman CN
J Clin Oncol; 1999 Jan; 17(1):168-72. PubMed ID: 10458230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
